Treatment of Advanced Hodgkin’s Disease with [1,3 Bis (2-Chloroethyl)-1-Nitrosourea] BCNU

Publisher Website
Google Scholar
Abstract
The nitrosoureas are a new class of antitumor agents that have demonstrated activity against several human tumors. BCNU, a member of this class, was used to treat 45 patients with far advanced, previously treated Hodgkin's disease. Twenty-one patients (47 per cent) achieved an appreciable remission. Nineteen patients had a partial remission for 16.5 weeks. Two patients had complete remissions for 72 and 208 weeks respectively. Leukopenia occurred in 24 patients, and thrombocytopenia in 32. BCNU has activity against Hodgkin's disease even when the disease is resistant to standard chemotherapeutic agents, and it appears not to be cross-resistant with the alkylating agents.